dr bennett's semaglutide obesitymedicine #weightloss #glp1 #flourishclinic #retatrutide #semaglutide #tirzepatide #evidencebasedcare #healthinnovation #southafrica #medicalethics #rantover Dr. Matthew Bennett, MD –

When medication is appropriate, the discussion should include: The limited evidence for GLP-1 agonists specifically in BED FDA-approved alternatives, including lisdexamfetamine Realistic expectations about outcomes and timeline Potential side effects and monitoring requirements Cost considerations and insurance coverage The importance of combining medication with behavioral interventions Monitoring during treatment should be systematic and multifaceted

however, human studies have not revealed significant abnormalities with first-trimester exposure

Oral versions of GLP-1s have also been approved, though they thus far have lower efficacy

5 You can take up to three months supply of your own medication out of the UK

The first draft of the manuscript was written by AO and HY, and all authors commented on previous versions of the manuscript